The University of Colorado Anschutz Medical Campus is going to be conducting a clinical study on the benefits of ‘Happy Mushrooms’ in a hope to help people who suffer from depression. Learn More about ‘Happy Mushrooms’ at the Curative Mushrooms website: https://www.curativemushrooms.com
Aurora, Colorado - The University of Colorado Anschutz Medical Campus proudly announces the initiation of its pioneering clinical trial involving a compound found in 'Happy Mushrooms' this fall. This landmark study aims to explore the therapeutic potential of this 'Happy Mushrooms' compound to treat treatment-resistant depression, a condition that traditional antidepressants often fail to address.
More can be learned about the health benefits of 'Happy Mushrooms' by going to the Curative Mushrooms website.
The trial, led by Dr. Andrew Novick, a psychiatrist, and Dr. Scott Thompson, a neuroscientist with the University of Colorado School of Medicine Department of Psychiatry, will be one of the first of its kind in the modern era in Colorado. This pivotal research follows an increasing national trend of psychedelic investigations, including those similar types of plants and indigenous medicine.
Notably, the trial will employ a unique approach to measure anhedonia, a severe symptom of depression marked by the inability to feel pleasure. Patients will be assessed using a tri-fold methodology that combines self-reporting, behavior monitoring in rewarding tasks, and innovative brain imaging techniques. This strategy aims to provide a more holistic and precise understanding of how this 'Happy Mushroom' compound might alleviate the debilitating effects of depression.
Dr. Thompson, a global leader in research of this 'Happy Mushroom' compound, emphasized the urgency of their mission, noting, "Major depressive disorder is one of the most common and costly neuropsychiatric syndromes. Traditional medications often fall short, and new treatments are sorely needed."
While the excitement around research of this 'Happy Mushroom' compound is palpable, both Dr. Novick and Dr. Thompson urge caution, emphasizing the importance of stringent clinical protocols to ensure participant safety.
The Colorado clinical trial using this "Happy Mushroom' compound will involve 40 participants, with the recruitment process prioritizing those already under the care of the University of Colorado School of Medicine's Department of Psychiatry prior to Spring 2023. Those interested in potential participation can find more information on the study at the University of Colorado Anschutz Medical Campus' website.
Both researchers express optimism about the trial's prospects. "We're dedicated to bringing the newest medicines to bear on psychiatric disease," remarked Dr. Thompson, a sentiment echoed by Dr. Novick: "We want to give patients the treatment they need and deserve."
People interested in obtaining their own 'Happy Mushrooms' at home can go to the Curative Mushrooms website for more information.
About University of Colorado Anschutz Medical Campus:
The University of Colorado Anschutz Medical Campus is a premier medical facility changing the face of medicine through education, research, innovation, and patient care.
